Clinical trial

Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC

NCT04153734

Drugs and interventions used in this trial

5 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Pembrolizumab Normalized identity: pembrolizumabView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Cis Platinum Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Carboplatin Normalized identity: carboplatinView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Pemetrexed Normalized identity: pemetrexedView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention nab paclitaxel Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC

Design: INTERVENTIONAL · Status: NOT YET RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2019-12-01

PhasePHASE2

Conditions

Locally Advanced Non-small Cell Lung Cancerunresolved

Interventions

PembrolizumabDRUG · verified · RxNorm: pembrolizumab

Cis PlatinumDRUG

CarboplatinDRUG · verified · RxNorm: carboplatin

PemetrexedDRUG · verified · RxNorm: pemetrexed

nab paclitaxelDRUG

Sponsors & collaborators

Kobe Minimally Invasive Cancer Centerlead sponsor

Merck Sharp & Dohme LLCcollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04153734 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.